The International Alpha Thalassemia Consortium, hosted by the UCSF Center for Maternal-Fetal Precision Medicine, brings together an interdisciplinary group of clinicians and scientists from around the world to focus expertise in hematology, maternal-fetal medicine, genetics, fetal therapy, and neonatology on alpha thalassemia major (ATM).
We gather quarterly in a virtual seminar to share advances, challenges, and best practices regarding clinical care for prenatal, pediatric, and adult patients diagnosed with ATM.
All are welcome.
Next Quarterly Seminar Speaker
Elina Vlachodimitropoulou, MBBS, PhD, MRCOG
King’s College London
Date TBD
Alpha Thalassemia Patient Registry
To refer a patient to the registry, please contact Billie.Lianoglou@ucsf.edu.
International Registry of Patients with Alpha Thalassemia (ATM Registry)
The aim of this registry is to prospectively and retrospectively collect data on patients who are diagnosed with alpha thalassemia major (ATM) and other alpha thalassemia mutations. Data collected will be used to:
- Understand the natural history of the disease
- Identify patient outcomes of therapies
- Improve clinical management of patients with ATM
- Improve medical decision making
- Improve quality of care
Past Seminars
September 26, 2024
Alpha Thalassemia Major Beyond the Neonatal Period: From a Pond of Knowledge to an Ocean of Unknowns
- Alpha thalassemia major was once considered a fatal condition, but with advances in perinatal care, more patients with this condition are surviving into adulthood. Given the rarity of this condition, our treatment has generally been based on strategies for beta thalassemia, though important differences warrant a unique approach. In this presentation, we will discuss our current treatment approach for these patients and review uncertainties that warrant further research.
January 23, 2024
Southeast Asian Ovalocytosis: An Alpha Thalassemia Major Imposter?
- Prenatal diagnosis of fetal anemia
- Epidemiology and typical presentation of homozygous Southeast Asian Ovalocytosis (compared to Alpha Thalassemia Major (ATM))
- Prenatal diagnosis of Southeast Asian Ovalocytosis (compared to ATM)
- Prognosis in untreated patients (compared to ATM) based on literature and our case series
- Conditions associated with Southeast Asian Ovalocytosis
November 7, 2023
Development of a Lentiviral Gene Therapy for Alpha Thalassemia
A recording is not available.
- An overview of gene therapy
- Beta globin lentiviral vectors developed for sickle cell disease
- Development of alpha globin lentiviral vectors for alpha thalassemia major (ATM) based on a clinical beta globin vectors
- Assessment of candidate lentiviral vectors in healthy donor and ATM patient hematopoietic stem and progenitor cells derived into red blood cells
August 15, 2023
Rapid Evolution in Management Strategy for Bart’s Hydrops Fetalis Syndrome – Singapore Experience
- Ethnic distribution in Singapore and magnitude of problem with Bart’s Hydrops Fetalis Syndrome (BHFS)
- Conventional practice for BHFS in Singapore
- Case presentations and lessons learnt
- Evolution of management including Intrauterine Transfusion (IUT)
- Future management strategy for BHFS in Singapore
May 4, 2023
Unrelated Donor Bone Marrow Transplantation for Thalassemia: Contrast with Gene Therapy
- Current results of unrelated donor hematopoietic stem cell transplantation (URD HCT) for thalassemia and key determinants that determine outcome
- URD HCT vs gene therapy for transfusion dependent thalassemias (TDT) with regard to accessibility and other considerations
- Key curative endpoints in curative therapies for TDT
February 15, 2023
Pharmacokinetics of Chelators in Infants with Alpha Thalassemia Major
- Review of chelators
- Challenges in dosing infants
- Model based dosing
November 15, 2022
Hypospadias Update: Definition and Treatment
Hypospadias is a condition that often develops in male fetuses with alpha thalassemia major.
- Standard versus severe hypospadias
- Embryology
- Etiology
- Treatment
- Outcomes
August 23, 2022
Developing Gene Therapy Strategies to Treat Alpha Thalassemia
- Three-pronged approach to develop gene therapies to cure alpha thalassemia major ex vivo
- In-depth look at CRISPR/AAV6-mediated genome editing correction strategy
- Future directions that include the potential adaptation of successful ex vivo strategies for in utero and postnatal in vivo delivery
May 9, 2022
Perinatal Management and Postnatal Transplant for Alpha Thalassemia Major: A Case from Netherlands
.
.
February 22, 2022
Patient Registry for Alpha Thalassemia: Deeper Understanding of Disease Outcomes
- Patients registry demographics
- Outcomes in patients that pursued fetal therapy
- Silver linings: unintended outcomes from referring provider collaborations
November 30, 2021
Iron Overload and Chelation Management in Patients with Alpha Thalassemia Major
- Risk of iron overload and its related complications in alpha thalassemia patients
- Standard of care practices for iron overload monitoring
- Review the currently available options for iron chelation
August 17, 2021
Technical Aspects of In Utero Transfusions for Alpha Thalassemia Major
- How and when to initiate invasive diagnostics and transfusion therapy in fetuses suspected to have alpha thalassemia
- Technical aspects of determining how much to transfuse, the frequency of transfusions, and the role and technical considerations for fetal exchange transfusion
- Troubleshooting strategies for difficult cases such as fetuses requiring transfusion at early gestational ages
May 20, 2021
Allogeneic Hematopoietic Stem Cell Transplantation for Alpha Thalassemia Major
- current practices in hematopoietic stem cell transplantation for ATM, and upcoming advances that improve survival of babies with ATM
